Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

A Positive Reaction to RBI's Status Quo
Tue, 7 Jun Closing

After witnessing buying interest in the post-noon trading session, the Indian equity markets continued their momentum and closed the day on a firm note. Most of the buying interest was seen after the RBI kept the benchmark repo rate unchanged at 6.5%. Stocks from sectors such as banking, consumer durables and realty led the gains.

The BSE Sensex closed higher by about 232 points (up 0.9%). The NSE Nifty ended higher by about 65 points (up 0.8%). The BSE Mid Cap ended higher by 0.3%, while the BSE Small Cap ended higher by about 1%.

On the global front, most of the Asian indices closed their day on a positive note. Hong Kong's Hang Seng ended higher by 1.42%, while Japan's Nikkei 225 closed with gains of 0.58%. The European indices also witnessed buying interest. The FTSE 100 was up 0.47%, France's CAC 40 gained 1.18% and Germany's DAX was up 1.66%. The rupee was trading at Rs 66.75 to the dollar at the time of writing.

Pharma stocks are trading mixed with IPCA Labs and Ajanta Pharma leading the gains. As per a leading financial daily, Gavis Pharmaceutical LLC, the US arm of Lupin Ltd has received a final nod from the US health regulator to launch Voriconazole tablets. The drug is used to treat infections in skin, abdomen, kidney, bladder wall and wounds.

Vfend tablets and Vfend oral suspension had sales of US$ 92.8 million and US$ 15.9 million, respectively in the US as at the end of FY16.

The company has stated that it shall commence marketing the drug in the US shortly.

Many companies including the likes of Ajanta Pharma and Zydus Cadila Pharma have received US FDA approvals to sell this drug. Hence, the competition seems to be tough in this segment.

Lupin is an India-based transnational pharmaceutical company. It is engaged in manufacturing and marketing of branded and generic formulations, and active pharmaceutical ingredients (APIs). The Mumbai-based firm has launched 9 products in the US market and received approvals for 20 products from the USFDA so far this fiscal. On an overall basis, over 160 product filings are pending for approval with the USFDA between Lupin and Gavis together. Lupin has a portfolio of 124 products in the US market.

Stock of Lupin closed the day up by around 1.3%.

Moving on to the news form the banking space. Axis Bank has raised US$ 500 million at the London stock exchange through the issue of green bonds. Green bonds are a relatively new asset class carrying a lower coupon rate and are a cheap source of finance.

The proceeds from the bonds will be invested in renewable energy, transportation and infrastructure projects. The notes have been issued at a price of 99.479 at a yield of 2.9%.

Talking about renewables, government has an ambitious target of 100 gigawatt (GW) solar energy by 2022. The funds raised could help to achieve this mammoth goal.

Now, here's a market update from our friends over at The Daily Profit Hunter...

Bank Nifty opened on a positive note at 17,796 ahead of the RBI credit policy announcement. It traded on a mildly positive note in the first half but took off post noon. It even managed to cross the 18,000 mark during the day. The index ended the day with gains of 1.56% at 17,946. We will now have to wait and watch whether bulls are able to take out the resistance of 18,000 immediately or are held back.

Bank Nifty Touches 8-Month High of 18,000

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

What else is happening in the markets today? Dig in...

Equitymaster requests your view! Post a comment on "A Positive Reaction to RBI's Status Quo". Click here!


Views on News

ITI Mid-Cap Fund: Investing in Potential Midcap Companies for Growth (Outside View)

Feb 26, 2021

PersonalFN analyses the features of ITI Mid-Cap Fund and explains the potential this fund has to offer to its investors.

NSE Glitch: Why Did the Market Go Up? (Fast Profits Daily)

Feb 26, 2021

In today's video, I'll discuss why thew stock market went up on Wednesday, 24 February 2021, when the NSE had to shut trading due to a technical glitch.

My Personal Checklist for Your Trading Success (Profit Hunter)

Feb 26, 2021

You my personal trading checklist and you will be well on your way to making it big as a trader.

Make Rs 5,000 Per Day Trading the Market (Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

Refresh Your Investment Portfolio in 2021 to Align with Your Financial Goals (Outside View)

Feb 25, 2021

Timely review of your investment portfolio is the key, to enable stable returns and work towards your envisioned financial goals during various market phases.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Intraday Trading for a Living (Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021 (Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla (Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.


India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms


Feb 26, 2021 (Close)